Sacubitril-valsartan, a common drug combination for heart failure, cuts the risk for cardiomyopathy after chemotherapy in patients who received anthracycline drugs by 77% in the first randomized ...
FDA labeling now recommends DPYD variant testing before initiating capecitabine or 5-FU, except when immediate treatment is clinically necessary. Complete DPD deficiency markedly impairs 5-FU ...
Most people who undergo chemotherapy do not develop heart failure. However, specific chemotherapy drugs may significantly increase your risk of heart failure and other cardiac problems. Chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results